Cargando…

Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease

SIMPLE SUMMARY: Similar to humans, dogs are affected by a variety of liver diseases with various causes and presentations. Recently, growing interest has focused on measuring markers of oxidative stress in patients with liver disease; however, no study to date has compared markers of oxidative stres...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Robert Kyle, Steiner, Jörg M., Suchodolski, Jan S., Lidbury, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958836/
https://www.ncbi.nlm.nih.gov/pubmed/36851386
http://dx.doi.org/10.3390/vetsci10020082
_version_ 1784895123681705984
author Phillips, Robert Kyle
Steiner, Jörg M.
Suchodolski, Jan S.
Lidbury, Jonathan A.
author_facet Phillips, Robert Kyle
Steiner, Jörg M.
Suchodolski, Jan S.
Lidbury, Jonathan A.
author_sort Phillips, Robert Kyle
collection PubMed
description SIMPLE SUMMARY: Similar to humans, dogs are affected by a variety of liver diseases with various causes and presentations. Recently, growing interest has focused on measuring markers of oxidative stress in patients with liver disease; however, no study to date has compared markers of oxidative stress between dogs with different liver diseases. This study aimed to evaluate markers of oxidative stress in dogs with different types of liver disease by measuring a compound known as 15-F(2t)-isoprostane in their urine. Among dogs with one of three different types of liver diseases, only those with a congenital portosystemic shunt (CPSS) had a significant increase in this oxidative stress marker when compared with a group of healthy control dogs. ABSTRACT: Isoprostanes are stable end products of lipid peroxidation that can be used as markers of oxidative stress. It was previously reported that a cohort of dogs with various liver diseases had increased urinary isoprostane concentrations compared to healthy control (HC) dogs. The aim of this study was to measure and report urinary isoprostane concentrations in dogs with different types of liver diseases. Urine was collected from 21 HC dogs and from 40 dogs with liver disease, including 25 with chronic hepatitis (CH), 7 with steroid hepatopathy (SH), and 8 with a congenital portosystemic shunt (CPSS). In this prospective, observational study, urinary 15-F(2t)-isoprostane (F(2)-IsoP) concentrations were measured by liquid chromatography/mass spectrometry and normalized to urinary creatinine concentrations. Concentrations were compared between groups using a Kruskal–Wallis test followed by Dunn’s multiple comparisons tests. Significance was set at p < 0.05. The median (range) urinary F(2)-IsoP to creatinine ratios (ng/mg UCr) were 3.6 (2.2–12.4) for HC dogs, 5.7 (2.4–11.3) for dogs with CH, 4.8 (2.4–8.6) for dogs with SH, and 12.5 (2.9–22.9) for dogs with CPSS. CPSS dogs had significantly higher urinary F(2)-IsoP concentrations than HC dogs (p = 0.004), suggesting increased oxidative stress among this cohort.
format Online
Article
Text
id pubmed-9958836
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99588362023-02-26 Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease Phillips, Robert Kyle Steiner, Jörg M. Suchodolski, Jan S. Lidbury, Jonathan A. Vet Sci Article SIMPLE SUMMARY: Similar to humans, dogs are affected by a variety of liver diseases with various causes and presentations. Recently, growing interest has focused on measuring markers of oxidative stress in patients with liver disease; however, no study to date has compared markers of oxidative stress between dogs with different liver diseases. This study aimed to evaluate markers of oxidative stress in dogs with different types of liver disease by measuring a compound known as 15-F(2t)-isoprostane in their urine. Among dogs with one of three different types of liver diseases, only those with a congenital portosystemic shunt (CPSS) had a significant increase in this oxidative stress marker when compared with a group of healthy control dogs. ABSTRACT: Isoprostanes are stable end products of lipid peroxidation that can be used as markers of oxidative stress. It was previously reported that a cohort of dogs with various liver diseases had increased urinary isoprostane concentrations compared to healthy control (HC) dogs. The aim of this study was to measure and report urinary isoprostane concentrations in dogs with different types of liver diseases. Urine was collected from 21 HC dogs and from 40 dogs with liver disease, including 25 with chronic hepatitis (CH), 7 with steroid hepatopathy (SH), and 8 with a congenital portosystemic shunt (CPSS). In this prospective, observational study, urinary 15-F(2t)-isoprostane (F(2)-IsoP) concentrations were measured by liquid chromatography/mass spectrometry and normalized to urinary creatinine concentrations. Concentrations were compared between groups using a Kruskal–Wallis test followed by Dunn’s multiple comparisons tests. Significance was set at p < 0.05. The median (range) urinary F(2)-IsoP to creatinine ratios (ng/mg UCr) were 3.6 (2.2–12.4) for HC dogs, 5.7 (2.4–11.3) for dogs with CH, 4.8 (2.4–8.6) for dogs with SH, and 12.5 (2.9–22.9) for dogs with CPSS. CPSS dogs had significantly higher urinary F(2)-IsoP concentrations than HC dogs (p = 0.004), suggesting increased oxidative stress among this cohort. MDPI 2023-01-21 /pmc/articles/PMC9958836/ /pubmed/36851386 http://dx.doi.org/10.3390/vetsci10020082 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Phillips, Robert Kyle
Steiner, Jörg M.
Suchodolski, Jan S.
Lidbury, Jonathan A.
Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease
title Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease
title_full Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease
title_fullStr Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease
title_full_unstemmed Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease
title_short Urinary 15-F(2t)-Isoprostane Concentrations in Dogs with Liver Disease
title_sort urinary 15-f(2t)-isoprostane concentrations in dogs with liver disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958836/
https://www.ncbi.nlm.nih.gov/pubmed/36851386
http://dx.doi.org/10.3390/vetsci10020082
work_keys_str_mv AT phillipsrobertkyle urinary15f2tisoprostaneconcentrationsindogswithliverdisease
AT steinerjorgm urinary15f2tisoprostaneconcentrationsindogswithliverdisease
AT suchodolskijans urinary15f2tisoprostaneconcentrationsindogswithliverdisease
AT lidburyjonathana urinary15f2tisoprostaneconcentrationsindogswithliverdisease